Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Looked at Q3 filing on Sedar again
View:
Post by N0taP00p on Apr 13, 2023 1:13am

Looked at Q3 filing on Sedar again

Burn rate for ACT is mentioned as $15M over 6 years, with possibility of big upside due to many factors. 

Said FDA submissions will be based on assessment of 25 patients @450 day,  in Q4 '22 (subject to blah blah...).    If this was delayed beyond Q1'23  and they didn't even mention it to shareholders till now, they will probably lose all trust and will struggle to raise money.  So I'm thinking the BTD application is in and we're in wait mode. 
 
My BEST GUESS from the financial statements is that they need ~$1.25M to $1.5M  per quarter to operate (with most of it going to ACT) , even after revenues from the laser division.  They had ~$2.5 M in working capital left end of Q3'22. So who knows, maybe they're close to running on fumes.   Insiders bought nearly $700K worth of shares (2.9 M) in Q3-Q4.   So I don't expect any more funding from there, unless RDW's aunt Martha wants to invest her pension in her favorite nephew's company.    
 
So it feels like all roads lead to them giving  it their best shot with the FDA , most ikely in Q1. Hoping the FDA approves. If they ask for more data or delay it for whatever reason, it'll be a sad day indeed. 
 
Comment by N0taP00p on Apr 13, 2023 3:58am
Key question is what result will weigh more on the FDA decision. Efficacy (good), safety (great), CR duration at any point in time (good), CR at 450 days (better than Keytruda but nowhere close to phase 1), patient convenience (quick treatments 6 months apart), etc.    And where is Health Canada in all this?  
Comment by Infinity on Apr 13, 2023 9:58pm
I understand that this is a very complex clinical test with multiple variables.  In addition they had the intitial 12 patients who were undertreated.  Covid did put a dent on pretty much everything and delayed many vital projects including TLT's.  What I fail to understand is the lack of communications from the management,  It is perfectly reasonable to let the share ...more  
Comment by N0taP00p on Apr 13, 2023 10:31pm
Infinity, pretty much a universal consensus on that on this board.  On the surface, it looks like an arrogant "don't care" attitude.  But the sheer duration of the news gap with no meaningful updates (see all the potential topics consultant99 mentioned before) has me hoping that  this time it is the real deal. If not, it's back to  being entertained by SF and ...more  
Comment by ScienceFirst on Apr 14, 2023 8:15am
N0taP00p  ... Not enough info?  Just a buzz word from you to look important.  A graduate of Bungee's kindergarden.  Just like FGPstuck.  Funny, we have: 1) MD&A, 2) news releases regarding presence at ASCO-GU, 3) news releases regarding AUA, 4) FDA Breakthrough timeline and a timeframe when they would apply, 5) Jan 3rd Biotuesday article, entereting discussions ...more  
Comment by N0taP00p on Apr 14, 2023 2:32pm
Your personal emotions seem to cloud your judgement a wee bit. But you're bright. 
Comment by Lesalpes29 on Apr 14, 2023 6:48am
Lack of communication actually could be because negociations are on with BP or other interested party. Why not? Next sign of life will be for AUA and financial report at the beginning of may. Patience!
Comment by N0taP00p on Apr 14, 2023 1:07pm
Alright, Lesalpes. Patience for 2 more weeks.  Btw, you and SF seem to spell negotiations the same way and seem to always agree with each other. Hmmm.... Not another id I hope. I thought the mind could only be bipolar not multipolar.    For now, will give you the benefit of the doubt.  Peace. 
Comment by BudFoxx2020 on Apr 14, 2023 8:21pm
SF runs this board with his 100s of multiple accounts.  Really a sad individual, a paid promoter or an employee.  If some one can not figure this out, stay away from penny stock and penny stock board.  Who in there right mind would spend the last 20 years 24/7 here posting the same thing over and over and chasing everyone away who has even a little bit of doubt.  This is a ...more  
Comment by Kingpin68 on Apr 14, 2023 9:04pm
Budfoxx, so you have no interest in this stock ? So you provide the service of scouring boards of stocks you don't like, and finding posters that don't have our best interests at heart. Thank you for your service sir, I'll sleep better tonight.
Comment by BudFoxx2020 on Apr 14, 2023 9:36pm
NP SF.   I am sure you will log in to a few more of your account to attack me before the night is done..  lololololololol.
Comment by Kingpin68 on Apr 14, 2023 10:03pm
Budfoxx, nobody needs to attack you, everytime you post you discredit yourself. I've learned never to trust anyone that uses 'lol' more than once.
Comment by BudFoxx2020 on Apr 15, 2023 5:03am
POINT PROVEN.   How may account cane and did exactly what I said.   Sad how these hustlers and promoters work the board and the amateurs falls for it every time...
Comment by Lesalpes29 on Apr 15, 2023 7:56am
Paranoia.... we are waiting for more results presented during next AUA, next financial, possible positive outcome from FDA... promoters my a...! A couple weeks to go and we will see where stand. GL
Comment by BudFoxx2020 on Apr 15, 2023 10:04am
Couple weeks.  Lol I will give you the whole YEAR.   Deal.  Lolololololol.  
Comment by Rumpl3StiltSkin on Apr 15, 2023 10:19am
Yep Lesalpes, We may not know about where we stand with BTD by then, yet I think we should see the CR %s improve nicely. With the better CR numbers it will be obvious to anyone with a pulse where this is going... Exception being BudFox maybe....
Comment by thadeush on Apr 15, 2023 6:10pm
ButtFox sounds much better on IGNORE.  *exhales happily*
Comment by BudFoxx2020 on Apr 15, 2023 7:05pm
Ohh another IGNORE.  Lol.  One of his 100s of account.  These guys are just scumbags.  Like I said. Easy bet forget couple of weeks.  How about end of the year.  And if nothing happens.  How about SF and his 100s of account stop posting and stop scamming the cancer survivors and hopefuls here.  It is fffing disgusting stringing people along for 20--+ years.  ...more  
Comment by Donein25 on Apr 14, 2023 9:45pm
Bud. If you don't care about the stock then do yourself a favor and leave. We will be just fine without your 0.02 cents. 
Comment by ScienceFirst on Apr 13, 2023 7:26am
N0taP00p ... Calm down.  And stop trying to come with all sorts of negative scenarios.  You've often been wrong in the past. TLT management brought us here, on a shoestring budget and have always solve issues.  TLT is no different than any other SMB or biotechs; it has to manage the burn rate.  And if you understand the micro and macro environment of biotechs, you'll ...more  
Comment by N0taP00p on Apr 13, 2023 9:38am
SF,  i hereby declare you the  winner of the Stockhouse "grand  fairytales"  category.  Awards are in May.  Bring your band. 
Comment by ScienceFirst on Apr 13, 2023 11:10am
N0taP00p ... Here's some fresh input and perspectives so you want to sound more credible and look more educated instead like posing like an uninformed in your next armchair quarterback posts. Q1 biotech layoffs rise 87% YOY, already halfway to 2022 total In the first quarter of 2023, 56 biopharmas laid off staff—an 87% jump over the same period in 2022, when 30 companies made cuts ...more  
Comment by Rumpl3StiltSkin on Apr 13, 2023 9:00am
Poop, chill! BTD brings all sorts of goodies. We probably will get a new CEO announcement right after that. We could also see some jv interest in TLT. Also, $$$$ will be less of an issue. You are correct when you say BTD has probably been applied for by now and we are in wait mode. There was nothing to report for BTD in Q4 last year because the clinicians still needed to tally the CR data ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250